TY - JOUR
T1 - Subcutaneous olanzapine for hyperactive or mixed delirium in patients with advanced cancer
T2 - A preliminary study
AU - Elsayem, Ahmed
AU - Bush, Shirley H.
AU - Munsell, Mark F.
AU - Curry, Eardie
AU - Calderon, Bianca B.
AU - Paraskevopoulos, Timotheos
AU - Fadul, Nada
AU - Bruera, Eduardo
N1 - Funding Information:
Eduardo Bruera, MD, is supported in part by grants RO1NR010162-01A1, RO1CA122292-01 , and RO1CA124481-01 from the National Institutes of Health . Mark Munsell, MD, is supported by the Cancer Center Support Grant and National Cancer Institute Grant P30-CA016672 .
PY - 2010/11
Y1 - 2010/11
N2 - Context: Oral olanzapine is effective in controlling agitation in patients with delirium, but often, parenteral administration is necessary. Intramuscular (IM) olanzapine is approved for managing agitation in schizophrenia, but this route is inappropriate for terminally ill patients. Objectives: The purpose of this pilot study was to determine the safety and tolerability of subcutaneous (SC) olanzapine in the management of hyperactive or mixed delirium in patients with advanced cancer. Methods: We conducted a prospective open-label study in patients with advanced cancer who had agitated delirium (Richmond Agitation Sedation Scale [RASS] score ≥+1) that had not responded to a 10 mg or higher dose of parenteral haloperidol over 24 hours. Patients received olanzapine 5 mg SC every eight hours for three days and continued haloperidol for breakthrough agitation. For patients requiring more than 8 mg of rescue haloperidol daily, the olanzapine dose was increased to 10 mg SC every eight hours. Injection site, systemic toxicity, and efficacy (RASS score <+1 and total haloperidol dose <8 mg per 24 hours on the last study day) were evaluated. Results: Twenty-four patients received at least one olanzapine injection, and 15 (63%) completed the study. Median age of evaluable patients was 58 years (range 49-79), and 67% were males. No injection site toxicity was observed after 167 injections. Probable systemic toxic effects were observed in four patients (severe hypotension [blood pressure <90/50 mm Hg], paradoxical agitation, diabetes insipidus, and seizure). Efficacy was achieved in nine (37.5%) patients. Conclusions: IM olanzapine is well tolerated subcutaneously. Further research is needed to evaluate its efficacy in controlling agitated delirium.
AB - Context: Oral olanzapine is effective in controlling agitation in patients with delirium, but often, parenteral administration is necessary. Intramuscular (IM) olanzapine is approved for managing agitation in schizophrenia, but this route is inappropriate for terminally ill patients. Objectives: The purpose of this pilot study was to determine the safety and tolerability of subcutaneous (SC) olanzapine in the management of hyperactive or mixed delirium in patients with advanced cancer. Methods: We conducted a prospective open-label study in patients with advanced cancer who had agitated delirium (Richmond Agitation Sedation Scale [RASS] score ≥+1) that had not responded to a 10 mg or higher dose of parenteral haloperidol over 24 hours. Patients received olanzapine 5 mg SC every eight hours for three days and continued haloperidol for breakthrough agitation. For patients requiring more than 8 mg of rescue haloperidol daily, the olanzapine dose was increased to 10 mg SC every eight hours. Injection site, systemic toxicity, and efficacy (RASS score <+1 and total haloperidol dose <8 mg per 24 hours on the last study day) were evaluated. Results: Twenty-four patients received at least one olanzapine injection, and 15 (63%) completed the study. Median age of evaluable patients was 58 years (range 49-79), and 67% were males. No injection site toxicity was observed after 167 injections. Probable systemic toxic effects were observed in four patients (severe hypotension [blood pressure <90/50 mm Hg], paradoxical agitation, diabetes insipidus, and seizure). Efficacy was achieved in nine (37.5%) patients. Conclusions: IM olanzapine is well tolerated subcutaneously. Further research is needed to evaluate its efficacy in controlling agitated delirium.
KW - Advanced cancer
KW - Hyperactive delirium
KW - Mixed delirium
KW - Olanzapine
KW - Subcutaneous route
UR - http://www.scopus.com/inward/record.url?scp=78349310565&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78349310565&partnerID=8YFLogxK
U2 - 10.1016/j.jpainsymman.2010.02.017
DO - 10.1016/j.jpainsymman.2010.02.017
M3 - Article
C2 - 20728301
AN - SCOPUS:78349310565
SN - 0885-3924
VL - 40
SP - 774
EP - 782
JO - Journal of pain and symptom management
JF - Journal of pain and symptom management
IS - 5
ER -